WO2025124584 - DEGRADABLE CATIONIC LIPID CONTAINING DISULFIDE BOND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/124584
Publication Date
19.06.2025
International Application No.
PCT/CN2024/139417
International Filing Date
13.12.2024
Title **
[English]
DEGRADABLE CATIONIC LIPID CONTAINING DISULFIDE BOND AND USE THEREOF
[French]
LIPIDE CATIONIQUE DÉGRADABLE CONTENANT UNE LIAISON DISULFURE ET SON UTILISATION
[Chinese]
一种含二硫键的可降解阳离子脂质及其应用
Applicants **
XIAMEN SINOPEG BIOTECH CO., LTD
Inventors
LIN, Minggui
ZHU, Qi
WANG, Ailan
CHEN, Dandan
WEI, Guohua
WENG, Wengui
LIU, Chao
LIN, Sheng
Priority Data
202311726611.X
15.12.2023
CN
202410365737.7
28.03.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2492 | |
| EPO | Filing, Examination, Granting | 18323 | |
| Japan | Filing, Examination, Granting | 2462 | |
| South Korea | Filing, Examination, Granting | 2828 | |
| USA | Filing, Examination, Granting | 5740 |
Total:
31,845
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
hydrocarbon derivative residue. A lipid composition prepared from the cationic lipid of the present invention can enable an LNP-nucleic acid pharmaceutical composition preparation to more fully exert a drug effect on the premise of having good capability for compounding a nucleic acid and a drug, in-vivo stability and low toxicity, thereby improving the immune or treatment effect.[French]
substitué ou non substitué. Une composition lipidique préparée à partir du lipide cationique de la présente invention peut permettre à une préparation de composition pharmaceutique LNP-acide nucléique d'exercer plus complètement un effet médicamenteux en raison de sa bonne capacité à combiner un acide nucléique et un médicament, de sa stabilité in vivo et de sa faible toxicité, ce qui permet d'améliorer l'effet immunitaire ou thérapeutique.[Chinese]
烃衍生物残基。用本发明的阳离子脂质制备的脂质组合物，在具备良好的核酸药物复合能力、体内稳定性和低毒性的前提下，能够使LNP-核酸药物组合物制剂更加充分地发挥药效，提高免疫或治疗效果。